Evidence map›Paper›PMID 36980766›Full record

ArticleCancers2023

LncRNA HCP5-Encoded Protein Regulates Ferroptosis to Promote the Progression of Triple-Negative Breast Cancer.

Xiao Tong, Zhengling Yu, Jiani Xing, Haizhou Liu, Shunheng Zhou, Yu'e Huang, Jing Lin, Wei Jiang, Lihong Wang

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiao TongDepartment of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
Zhengling YuDepartment of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
Jiani XingDepartment of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
Haizhou LiuDepartment of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
Shunheng ZhouDepartment of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.ORCID 0000-0003-0299-2667
Yu'e HuangDepartment of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
Jing LinInstitute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Science, Harbin Medical University, Harbin 150081, China.
Wei JiangDepartment of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.ORCID 0000-0003-1591-4721
Lihong WangDepartment of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
Nanjing University of Aeronautics and Astronautics · CNSoutheast University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides and were initially believed to lack encoding capability. However, recent research has found open reading frames (ORFs) within lncRNAs, suggesting that they may have coding capacity. Despite this discovery, the mechanisms by which lncRNA-encoded products are involved in cancer are not well understood. The current study aims to investigate whether lncRNA HCP5-encoded products promote triple-negative breast cancer (TNBC) by regulating ferroptosis.

methodsWe used bioinformatics to predict the coding capacity of lncRNA HCP5 and conducted molecular biology experiments and a xenograft assay in nude mice to investigate the mechanism of its encoded products. We also evaluated the expression of the HCP5-encoded products in a breast cancer tissue microarray.

resultsOur analysis revealed that the ORF in lncRNA HCP5 can encode a protein with 132-amino acid (aa), which we named HCP5-132aa. Further experiments showed that HCP5-132aa promotes TNBC growth by regulating GPX4 expression and lipid ROS level through the ferroptosis pathway. Additionally, we found that the breast cancer patients with high levels of HCP5-132aa have poorer prognosis.

conclusionsOur study suggests that overexpression of lncRNA HCP5-encoded protein is a critical oncogenic event in TNBC, as it regulates ferroptosis. These findings could provide new therapeutic targets for the treatment of TNBC.

Indexed as

encoded proteinferroptosislncRNA HCP5ROStriple-negative breast cancer

Identifiers

PMID36980766
PMCPMC10046773
OpenAlexW4328122026

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read53
table measurements read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.